Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Aligos Therapeutics Analyst Ratings and Price Targets | NASDAQ:ALGS | Benzinga
Aligos Therapeutics Inc has a consensus price target of $20.5 based on the ratings of 4 analysts. The high is $70 issued by HC Wainwright & Co. on March 11, 2025. The low is $2 issued by SVB Leerink on November 3, 2022. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on March 11, 2025, November 7, 2024, and October 23, 2024, respectively. With an average price target of $73.33 between HC Wainwright & Co., there's an implied 527.95% upside for Aligos Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Piper Sandler
Jefferies
SVB Leerink
1calculated from analyst ratings
Analyst Ratings for Aligos Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/11/2025 | Buy Now | 499.41% | HC Wainwright & Co. | Ed Arce62% | $75 → $70 | Maintains | Buy | Get Alert |
| 11/07/2024 | Buy Now | 542.22% | HC Wainwright & Co. | Ed Arce62% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
| 10/23/2024 | Buy Now | 542.22% | HC Wainwright & Co. | Ed Arce62% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
| 09/20/2024 | Buy Now | 542.22% | HC Wainwright & Co. | Ed Arce62% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
| 08/19/2024 | Buy Now | 542.22% | HC Wainwright & Co. | Ed Arce62% | → $75 | Initiates | → Buy | Get Alert |
| 01/17/2023 | Buy Now | -40.06% | Piper Sandler | Yasmeen Rahimi61% | $75 → $175 | Maintains | Overweight | Get Alert |
| 01/06/2023 | Buy Now | -74.31% | Piper Sandler | Yasmeen Rahimi61% | $50 → $75 | Upgrade | Neutral → Overweight | Get Alert |
| 01/06/2023 | Buy Now | -74.31% | Jefferies | Michael Yee56% | $62.5 → $75 | Upgrade | Hold → Buy | Get Alert |
| 11/03/2022 | Buy Now | -82.87% | SVB Leerink | Roanna Ruiz35% | $75 → $50 | Maintains | Market Perform | Get Alert |
| 05/05/2022 | Buy Now | -74.31% | SVB Leerink | Roanna Ruiz35% | $175 → $75 | Downgrade | Outperform → Market Perform | Get Alert |
FAQ
What is the target price for Aligos Therapeutics (ALGS) stock?
The latest price target for Aligos Therapeutics (NASDAQ:ALGS) was reported by HC Wainwright & Co. on March 11, 2025. The analyst firm set a price target for $70.00 expecting ALGS to rise to within 12 months (a possible 499.41% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aligos Therapeutics (ALGS)?
The latest analyst rating for Aligos Therapeutics (NASDAQ:ALGS) was provided by HC Wainwright & Co., and Aligos Therapeutics maintained their buy rating.
When was the last upgrade for Aligos Therapeutics (ALGS)?
The last upgrade for Aligos Therapeutics Inc happened on January 6, 2023 when Piper Sandler raised their price target to $3. Piper Sandler previously had a neutral for Aligos Therapeutics Inc.
When was the last downgrade for Aligos Therapeutics (ALGS)?
The last downgrade for Aligos Therapeutics Inc happened on May 5, 2022 when SVB Leerink changed their price target from $7 to $3 for Aligos Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Aligos Therapeutics (ALGS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aligos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aligos Therapeutics was filed on March 11, 2025 so you should expect the next rating to be made available sometime around March 11, 2026.
Is the Analyst Rating Aligos Therapeutics (ALGS) correct?
While ratings are subjective and will change, the latest Aligos Therapeutics (ALGS) rating was a maintained with a price target of $75.00 to $70.00. The current price Aligos Therapeutics (ALGS) is trading at is $11.68, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.